Year All20242023202220212020 Dec 10, 2024 Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program PDF Version Nov 07, 2024 Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update PDF Version Nov 05, 2024 Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference PDF Version Oct 14, 2024 Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 PDF Version Aug 29, 2024 Q32 Bio to Participate in Upcoming September Investor Conferences PDF Version Aug 08, 2024 Q32 Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update PDF Version Jul 09, 2024 Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis PDF Version Jul 01, 2024 Q32 Bio Joins Russell 3000® Index PDF Version May 09, 2024 Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update PDF Version Apr 03, 2024 Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer PDF Version
Dec 10, 2024 Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program PDF Version
Nov 07, 2024 Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update PDF Version
Nov 05, 2024 Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference PDF Version
Oct 14, 2024 Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 PDF Version
Aug 08, 2024 Q32 Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update PDF Version
Jul 09, 2024 Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis PDF Version
May 09, 2024 Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update PDF Version